Market capitalization | $12.92b |
Enterprise Value | $20.66b |
P/E (TTM) P/E ratio | 34.42 |
EV/FCF (TTM) EV/FCF | 52.84 |
EV/Sales (TTM) EV/Sales | 2.49 |
P/S ratio (TTM) P/S ratio | 1.56 |
P/B ratio (TTM) P/B ratio | 3.96 |
Revenue growth (TTM) Revenue growth | 1.28% |
Revenue (TTM) Revenue | $8.31b |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
12 Analysts have issued a Solventum forecast:
12 Analysts have issued a Solventum forecast:
Mar '25 |
+/-
%
|
||
Revenue | 8,307 8,307 |
1%
1%
|
|
Gross Profit | 4,606 4,606 |
3%
3%
|
|
EBITDA | 1,429 1,429 |
37%
37%
|
EBIT (Operating Income) EBIT | 886 886 |
48%
48%
|
Net Profit | 378 378 |
71%
71%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Solventum Corp. operates as a health care company. The company was founded on January 24, 2023 and is headquartered in Maplewood, MN.
Head office | United States |
CEO | Bryan Hanson |
Employees | 22,000 |
Website | www.solventum.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.